ONK Therapeutics, is an innovative cell therapy company dedicated to developing a next generation of off-the-shelf, dual-targeted NK cell therapy platform targeting solid and hematological cancers.
Onk Therapeutics has raised €26M across 2 funding rounds, most recently a Series A round in Jan 2022. Based in Galway, Ireland; founded 2015; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2022-01-07 | Series A | €19M | — | View deal → |
| 2020-10-19 | Other | €6.8M | — | View deal → |
